Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Comprehensive management of pressure ulcers in spinal cord injury: current concepts and future trends.

Kruger EA, Pires M, Ngann Y, Sterling M, Rubayi S.

J Spinal Cord Med. 2013 Nov;36(6):572-85. doi: 10.1179/2045772313Y.0000000093. Epub 2013 May 21. Review.

2.

Mohs versus surgical excision in nonmelanoma skin cancers: does location matter?

Pereira CT, Kruger EA, Sayer G, Kim J, Hu J, Miller TA, Rudkin GH.

Ann Plast Surg. 2013 Apr;70(4):432-4. doi: 10.1097/SAP.0b013e3182834b47.

PMID:
23486132
3.

In vitro mineralization of human mesenchymal stem cells on three-dimensional type I collagen versus PLGA scaffolds: a comparative analysis.

Kruger EA, Im DD, Bischoff DS, Pereira CT, Huang W, Rudkin GH, Yamaguchi DT, Miller TA.

Plast Reconstr Surg. 2011 Jun;127(6):2301-11. doi: 10.1097/PRS.0b013e318213a004.

PMID:
21617464
4.

Extracellular-signal-related kinase 1/2 is responsible for inhibition of osteogenesis in three-dimensional cultured MC3T3-E1 cells.

Im DD, Kruger EA, Huang WR, Sayer G, Rudkin GH, Yamaguchi DT, Jarrahy R, Miller TA.

Tissue Eng Part A. 2010 Nov;16(11):3485-94. doi: 10.1089/ten.TEA.2010.0222. Epub 2010 Sep 9.

PMID:
20590408
5.

Histologic effects of autologous platelet gel in skin flap healing.

Chandra RK, Handorf C, West M, Kruger EA, Jackson S.

Arch Facial Plast Surg. 2007 Jul-Aug;9(4):260-3.

PMID:
17638760
6.

The role of therapeutic angiogenesis in tissue repair and regeneration.

Li WW, Talcott KE, Zhai AW, Kruger EA, Li VW.

Adv Skin Wound Care. 2005 Nov-Dec;18(9):491-500; quiz 501-2. Review.

PMID:
16365547
8.

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.

Ng SS, Gütschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD.

Cancer Res. 2003 Jun 15;63(12):3189-94.

9.

Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay.

Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M, Feldman AL, Figg WD, Alexander HR, Liu ET, Kohn EC, Libutti SK.

Biotechniques. 2002 Sep;33(3):664-6, 668, 670.

PMID:
12238776
10.

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

Figg WD, Kruger EA, Price DK, Kim S, Dahut WD.

Invest New Drugs. 2002 May;20(2):183-94. Review.

PMID:
12099578
11.

The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.

Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.

Clin Cancer Res. 2002 Apr;8(4):1242-50.

12.

5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis.

Price DK, Ando Y, Kruger EA, Weiss M, Figg WD.

Ther Drug Monit. 2002 Feb;24(1):104-10.

PMID:
11805730
13.

Approaches to preclinical screening of antiangiogenic agents.

Kruger EA, Duray PH, Price DK, Pluda JM, Figg WD.

Semin Oncol. 2001 Dec;28(6):570-6. Review.

PMID:
11740811
14.

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL.

Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6.

PMID:
11685731
15.

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Krüger EA, Gubish E, Pluda JM, Reed E.

Clin Cancer Res. 2001 Jul;7(7):1888-93.

17.

Thalidomide neuropathy in patients treated for metastatic prostate cancer.

Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD.

Muscle Nerve. 2001 Aug;24(8):1050-7.

PMID:
11439380
18.

TNP-470: an angiogenesis inhibitor in clinical development for cancer.

Kruger EA, Figg WD.

Expert Opin Investig Drugs. 2000 Jun;9(6):1383-96. Review.

PMID:
11060750
19.

The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.

Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BK, Hewitt S, Figg WD, Alexander HR, Libutti SK.

J Surg Res. 2000 Jun 1;91(1):26-31.

PMID:
10816345
20.

Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.

Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD.

Biochem Biophys Res Commun. 2000 Feb 5;268(1):183-91.

PMID:
10652234
21.

UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.

Kruger EA, Blagosklonny MV, Dixon SC, Figg WD.

Invasion Metastasis. 1998-1999;18(4):209-18.

PMID:
10640907
22.
23.

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Dixon SC, Kruger EA, Bauer KS, Figg WD.

Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84.

PMID:
10357564
24.

Personnel management; role of the noncommissioned officer in charge.

KRUGER EA.

Med Techn Bull. 1955 Mar-Apr;6(2):58-60. No abstract available.

PMID:
14369277

Supplemental Content

Loading ...
Support Center